Hikma Financial Statements From 2010 to 2024
| HKMPF Stock | USD 22.33 1.92 7.92% |
Check Hikma Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Hikma main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Hikma financial statements analysis is a perfect complement when working with Hikma Pharmaceuticals Valuation or Volatility modules.
Hikma |
Hikma Pharmaceuticals PLC Company Profit Margin Analysis
Hikma Pharmaceuticals' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Hikma Pharmaceuticals Profit Margin | 0.14 % |
Most of Hikma Pharmaceuticals' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hikma Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Hikma Pharmaceuticals PLC has a Profit Margin of 0.1357%. This is 101.21% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The profit margin for all United States stocks is 110.69% lower than that of the firm.
Hikma Pharmaceuticals PLC Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Hikma Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Hikma Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hikma Pharmaceuticals competition to find correlations between indicators driving Hikma Pharmaceuticals's intrinsic value. More Info.Hikma Pharmaceuticals PLC is one of the top stocks in return on equity category among related companies. It is one of the top stocks in return on asset category among related companies reporting about 0.50 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Hikma Pharmaceuticals PLC is roughly 2.00 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Hikma Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Hikma Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hikma Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Hikma Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Hikma Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Hikma Pharmaceuticals investors use historical funamental indicators, such as Hikma Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Hikma Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Hikma Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Hikma Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Hikma Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Hikma Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company was founded in 1978 and is based in London, the United Kingdom. Hikma Pharmaceutical operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 8700 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Hikma Pharmaceuticals Correlation against competitors. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Hikma Pink Sheet analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |